Biopharma Firm Applies to Produce Large Quantities of Controlled Meds
Published Date: 8/11/2025
Notice
Summary
Biopharmaceutical Research Company wants to get official approval to make large amounts of certain controlled substances. This affects anyone tracking or regulating these drugs and could speed up research and development. Keep an eye out for updates on approval timing and any related fees.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Application to Bulk-Manufacture Controlled Drugs
Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic classes of controlled substances. This affects people and organizations that track or regulate these drugs and could speed up research and development.
Watch for Approval Timing and Fees
The notice advises stakeholders to watch for updates on approval timing and any related fees. If you are an applicant, regulator, or otherwise involved with these drugs, future notices may announce when approval happens and whether fees apply.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
2026-15328, Joan Rubinger, N.P.; Decision and Order
2026-15201, Gene M. Koop, D.D.S.; Decision and Order
2026-15199, Kerri Zavota, DVM; Decision and Order
Previous / Next Documents
Previous: 2025-15161, Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals
Chattem Chemicals wants to get official approval to make large amounts of certain controlled substances. This affects anyone involved in drug manufacturing and regulation, as it could change who supplies these important chemicals. Keep an eye out for updates on approvals and any new rules that might come with this change.
Next: 2025-15164, Notice of Public Hearing and Request for Comments on the Fair Market Value and Maximum Economic Recovery for the Little Eccles Coal Lease by Application, UTU-92226, in Emery County, Utah
The Bureau of Land Management wants your thoughts on how much the coal in the Little Eccles lease in Emery County, Utah, is really worth and how much can be profitably mined. This affects local communities, coal companies, and anyone interested in land use and energy resources. Speak up soon—your comments could shape the lease’s future value and mining plans!